Search

Your search keyword '"Nosbaum, A."' showing total 1,345 results
Start Over Author "Nosbaum, A."
1,345 results on '"Nosbaum, A."'

254. Unique molecular signatures typify skin inflammation induced by chemical allergens and irritants

Author

UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Centre de l'allergie, UCL - (SLuc) Service de dermatologie, Lefevre, Marine‐Alexia, Nosbaum, Audrey, Rozieres, Aurore, Lenief, Vanina, Mosnier, Amandine, Cortial, Angèle, Prieux, Margaux, De Bernard, Simon, Nourikyan, Julien, Jouve, Pierre‐Emmanuel, Buffat, Laurent, Hacard, Florence, Ferrier‐Lebouedec, Marie‐Christine, Pralong, Pauline, Dzviga, Charles, Herman, Anne, Baeck, Marie, Nicolas, Jean‐François, Vocanson, Marc, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Centre de l'allergie, UCL - (SLuc) Service de dermatologie, Lefevre, Marine‐Alexia, Nosbaum, Audrey, Rozieres, Aurore, Lenief, Vanina, Mosnier, Amandine, Cortial, Angèle, Prieux, Margaux, De Bernard, Simon, Nourikyan, Julien, Jouve, Pierre‐Emmanuel, Buffat, Laurent, Hacard, Florence, Ferrier‐Lebouedec, Marie‐Christine, Pralong, Pauline, Dzviga, Charles, Herman, Anne, Baeck, Marie, Nicolas, Jean‐François, and Vocanson, Marc

Abstract

Background Skin exposure to chemicals may induce an inflammatory disease known as contact dermatitis (CD). Distinguishing the allergic and irritant forms of CD often proves challenging in the clinic. Methods To characterize the molecular signatures of chemical-induced skin inflammation, we conducted a comprehensive transcriptomic analysis on the skin lesions of 47 patients with positive patch tests to reference contact allergens and nonallergenic irritants. Results A clear segregation was observed between allergen- and irritant-induced gene profiles. Distinct modules pertaining to the epidermal compartment, metabolism, and proliferation were induced by both contact allergens and irritants; whereas only contact allergens prompted strong activation of adaptive immunity, notably of cytotoxic T-cell responses. Our results also confirmed that: (a) unique pathways characterize allergen- and irritant-induced dermatitis; (b) the intensity of the clinical reaction correlates with the magnitude of immune activation. Finally, using a machine-learning approach, we identified and validated several minimal combinations of biomarkers to distinguish contact allergy from irritation. Conclusion These results highlight the value of molecular profiling of chemical-induced skin inflammation for improving the diagnosis of allergic versus irritant contact dermatitis.

Published
2021

255. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy:baseline characteristics of participants on the EUROSTAD prospective observational study

Author

Bruin-Weller, Marjolein de, Pink, Andrew E., Patrizi, Annalisa, Gimenez-Arnau, Ana M., Agner, Tove, Roquet-Gravy, Pierre Paul, Ferrucci, Silvia M., Arenberger, Petr, Svensson, Ake, Schuttelaar, Marie L.A., Nosbaum, Audrey, Jayawardena, Shyamalie, Rizova, Elena, Ardeleanu, Marius, Eckert, Laurent, Ozturk, Zafer E., Bruin-Weller, Marjolein de, Pink, Andrew E., Patrizi, Annalisa, Gimenez-Arnau, Ana M., Agner, Tove, Roquet-Gravy, Pierre Paul, Ferrucci, Silvia M., Arenberger, Petr, Svensson, Ake, Schuttelaar, Marie L.A., Nosbaum, Audrey, Jayawardena, Shyamalie, Rizova, Elena, Ardeleanu, Marius, Eckert, Laurent, and Ozturk, Zafer E.

Abstract

Background: Insights into the real-world treatment paradigm and long-term burden of atopic dermatitis (AD) are needed to inform clinical and health policy decisions. Methods: The prospective, observational EUROSTAD study enrolled adults with moderate-to-severe AD starting or switching systemic therapy (51 sites in 10 European countries). We report the baseline characteristics, treatment patterns, and outcomes of these patients using descriptive statistics. Results: A 12-month enrollment period of EUROSTAD was completed and 308 patients were enrolled: average age 37 years, AD duration 25 years, 43% were female. Most patients reported use of systemic therapy (93%) and ≥1 atopic comorbidity (82%). Mean [standard deviation] disease severity/burden measures were high: Investigator’s Global Assessment (3.1 [0.8]), Eczema Area and Severity Index (16.2 [10.9]), Peak Pruritus Numerical Rating Scale (5.5 [2.5]), sleep impairment Visual Analog Scale (49.8 [31.6]) scores, and time lost from work (4.1 [13.7] days/year) or usual activities (16.8 [38.7] days/year). Most patients showed borderline or clinical levels of anxiety (59%) and/or depression (63%) using the Hospital Anxiety and Depression Scale. Conclusions: Adults with moderate-to-severe AD starting/switching systemic treatment enrolled in EUROSTAD have a high burden of longstanding disease despite continuous use of topical drugs, emollients, and systemic therapies.

Published
2021

256. Disease burden and treatment history among adults with atopic dermatitis receiving systemic therapy: baseline characteristics of participants on the EUROSTAD prospective observational study

Author

MS Dermatologie/Allergologie, Infection & Immunity, Bruin-Weller, M.D., Pink, A.E., Patrizi, A., Gimenez-Arnau, A.M., Agner, T., Roquet-Gravy, P.-P., Ferrucci, S.M., Arenberger, P., Svensson, A., Schuttelaar, M.L.A., Nosbaum, A., Jayawardena, S., Rizova, E., Ardeleanu, M., Eckert, L., Ozturk, Z.E., MS Dermatologie/Allergologie, Infection & Immunity, Bruin-Weller, M.D., Pink, A.E., Patrizi, A., Gimenez-Arnau, A.M., Agner, T., Roquet-Gravy, P.-P., Ferrucci, S.M., Arenberger, P., Svensson, A., Schuttelaar, M.L.A., Nosbaum, A., Jayawardena, S., Rizova, E., Ardeleanu, M., Eckert, L., and Ozturk, Z.E.

Published
2021

274. Molecular diagnosis of skin allergy

Author

Lefevre, Marine-Alexia, Nosbaum, Audrey, Hacard, Florence, Berard, Frederic, Baeck, Marie, Herman, Anne, Bruze, Magnus, Svedman, Cecilia, Nicolas, Jean-François, and Vocanson, Marc

Published
2020
Full Text
View/download PDF

281. Management of urticaria by French specialists compared to international guideline recommendations

Author

Berard, F., Viguier, M., Lefevre, S., Vigan, M., Barzegar, C., Boussaid, R., Hacard, F., Gabison, G., Staumont, D., Marmion, N., Pouplard, C., Delaunay, J., Badaoui, A., Nosbaum, A., Pralong, P., Castelain, F., Bouillet, L., Sarre, M.E., Vermeulen, C., Tetart, F., Bachtarzi, Z., Doutre, M.S., Martinache, C., Bara, C., Augey, F., Boccon Gibod, I., Nicolas, J.F., Maatouk, I., Mathelier Fusade, P., Soutou, B., Goujon Henry, C., Hoarau, C., Crépy, M.N., Bernier, C., Cambazard, F., Guinepain, M.T., Amsler, Emmanuelle, Du Thanh, Aurelie, and Soria, Angèle

Published
2020
Full Text
View/download PDF

284. When Joints Fail: Identifying the Allergen Helps

Author

Sébastien Lustig, Jean-François Nicolas, Marc Vocanson, Audrey Nosbaum, Department of Allergology and Clinical Immunology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, parent, Laboratoire de Biomécanique et Mécanique des Chocs (LBMC UMR T9406 ), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Gustave Eiffel, Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Cadic, Ifsttar, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
ALLERGENS, Allergen, business.industry, MEDLINE, medicine, ASTHMA, Immunology and Allergy, HUMANS, Computational biology, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, medicine.disease_cause, business, [SDV.IMM.ALL] Life Sciences [q-bio]/Immunology/Allergology
Abstract

More than 1 million joint replacement surgeries are performed each year in the United States, and failure occurs in 10% of them, raising major health and economic burdens. The reasons for failure are multiple and include malposition, infection, and hypersensitivity (HS)/allergy to implant components. The term "hypersensitivity", defining an inflammatory reaction to the implant components, is more appropriate than the term "allergy," because the implant-induced inflammation can be mediated by innate or adaptive immunity. Implant HS, also sometimes called "adverse reaction to metal debris" or "pseudotumor- like periprosthetic tissue reactions" in the specific condition or metal-on-metal hip replacement, undoubtedly exists, but it cannot be stated to always be an allergic reaction. Innate HS, also referred to as nonallergic HS, may develop in response to the generation of metal/polymer wear debris, which causes local inflammation due to activation of macrophages, thus leading to osteoclast triggering, bone resorption, and implant loosening. There is no diagnostic test for nonallergic HS. Conversely, adaptive HS, that is, allergy to prosthesis, also called type IV HS, is mediated by specific T cells that infiltrate the periimplant tissue where they are activated by antigen-presenting cells. The main allergens are metals (nickel, chromium, cobalt) and bone cement compounds. T-cell activation leads to the recruitment of leucocytes, which will cause joint inflammation, pain, and loosening.

Published
2021
Full Text
View/download PDF

289. Diagnostic moléculaire de l’eczéma de contact allergique

Author

Lefevre, M.A., primary, Nosbaum, A., additional, Rozières, A., additional, Lenief, V., additional, Mosnier, A., additional, De Bernard, S., additional, Nourikyan, J., additional, Buffat, L., additional, Hacard, F., additional, Ferrier-Lebouedec, M.C., additional, Pralong, P., additional, Dzviga, C., additional, Herman, A., additional, Baeck, M., additional, Nicolas, J.F., additional, and Vocanson, M., additional

Published
2021
Full Text
View/download PDF

294. Test d’applications répétées au gant: confirmation de son intérêt pour le diagnostic d’allergie de contact

Author

Bertolotti Potachin, L., Lamouroux, C., Charbotel, B., Nosbaum, A., Pralong, P., Pasteur, J., Clément, A., Hacard, F., and Nicolas, J.F.

Abstract

L’eczéma des mains représente 80 % des dermatoses professionnelles en Europe. Les gants sont les premiers équipements de protection individuelle pourvoyeurs de dermatose professionnelle. Ils sont impliqués majoritairement dans les eczémas irritatifs et allergiques de contact (EAC). Un test d’application répétée au gant (GRAT pour Glove Repeated Application Test) a été proposé pour améliorer la démarche diagnostique de l’allergie de contact aux gant. Il consiste à appliquer un morceau de la face interne du gant de 3×3cm sur la même zone de la face interne de l’avant-bras pendant 10 nuits consécutives, le morceau de gant étant maintenu par une bande non adhésive. Une première étude a été réalisée chez 58 patients montrant que ce test semblait pertinent dans la démarche diagnostique d’EAC au gant. Notre étude, avec une cohorte de patients plus importante, a pour objectif de confirmer ce résultat.

Published
2024
Full Text
View/download PDF

295. Réponses immunitaires associées à la voie de signalisation JAK/STAT dans les dermatoses inflammatoires: comparaison de l’expression moléculaire et transcriptomique cutanée dans l’hidradénite suppurée, le psoriasis et la dermatite atopique

Author

Klepfisch, L., Chircop, I., Bourdenet, V., Dumas, A., Chastagner, M., Kanitakis, J., Lenief, V., Lopez, J., Nazim, B., Brocard, J., Harou, O., Nicolas, J.F., Jullien, D., Nosbaum, A., Vocanson, M., and Villani, A.

Abstract

La voie de signalisation JAK-STAT transduit l’activité biologique de multiples cytokines et constitue donc une cible thérapeutique de choix pour les maladies inflammatoires cutanées. Notre but était de déterminer la spécificité d’activation des différentes voies JAK/STATs et cytokiniques associées dans 3 dermatoses inflammatoires: l’hidradénite suppurée (HS), le psoriasis (PSO) et la dermatite atopique (DA).

Published
2024
Full Text
View/download PDF

296. Réévaluation de l’imputabilité médicamenteuse dans la survenue d’éruptions eczématiformes chroniques du sujet âgé par comparaison aux données du SNDS dans la population générale

Author

Tétart, F., Bouteiller, J., Thill, C., Guérin, O., Lacroix, E., Delaunay, J., Jachiet, M., Bara, C., Nosbaum, A., Bouschon, P., Milpied, B., Oro, S., Assier, H., Guelimi, R., Valois, A., Viguier, M., Dezoteux, F., Staumont-Sallé, D., Boulard, C., Brenaut, E., Morice, C., Droitcourt, C., Ferrier Le Bouedec, M.C., Pasteur, J., Raison-Peyron, N., Grosjean, J., and Joly, P.

Abstract

Les éruptions eczématiformes chroniques du sujet âgé (EECSA) sont un motif fréquent de consultation. Les inhibiteurs calciques ont été mis en cause dans deux études, mais d’autres médicaments comme les diurétiques thiazidiques, les antiagrégants et les statines ont également été suspectés. L’objectif de l’étude a été de réévaluer l’imputabilité de certaines classes de médicaments dans la survenue d’une EECSA sans cause.

Published
2024
Full Text
View/download PDF

298. De novo psoriasis in atopic dermatitis patients treated with dupilumab: a retrospective cohort

Author

Carle Paul, Hélène Aubert, A. Marchetti, Audrey Nosbaum, Marie Tauber, A. Valois, L. Jaulent, Bruno Sassolas, Jean-François Nicolas, and Delphine Staumont-Sallé

Subjects
medicine.medical_specialty, business.industry, MEDLINE, Pustular psoriasis, Retrospective cohort study, Dermatology, Atopic dermatitis, Antibodies, Monoclonal, Humanized, medicine.disease, Dupilumab, Dermatitis, Atopic, Infectious Diseases, Psoriasis, Humans, Medicine, business, Retrospective Studies
Published
2020
Full Text
View/download PDF

299. Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis

Author

Aurélie Du-Thanh, Audrey Nosbaum, Angèle Soria, Fatma Jendoubi, M-C Ferrier le Bouedec, Nadia Raison-Peyron, A. Valois, Marie Jachiet, Sébastien Barbarot, Audrey Lasek, P. Marcant, R. Merhi, P. Balayé, Delphine Staumont-Sallé, and Florence Tetart

Subjects
Moderate to severe, medicine.medical_specialty, business.industry, Eczema, Hypereosinophilia, Dermatology, Atopic dermatitis, medicine.disease, Antibodies, Monoclonal, Humanized, Dupilumab, Severity of Illness Index, Dermatitis, Atopic, Infectious Diseases, Treatment Outcome, Eosinophilia, Medicine, Humans, In patient, medicine.symptom, business
Published
2020

300. La formation en allergologie en France en 2020

Author

Frédéric Bérard, Audrey Nosbaum, K. Nakara, Jean-François Nicolas, CHU Grenoble, Immunologie de l'allergie cutanée et vaccination – Immunology of skin allergy and vaccination, Centre International de Recherche en Infectiologie (CIRI), École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure de Lyon (ENS de Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre International de Recherche en Infectiologie - UMR (CIRI), École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CCSD, Accord Elsevier, Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-École normale supérieure - Lyon (ENS Lyon)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV] Life Sciences [q-bio], 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, [SDV]Life Sciences [q-bio], Immunology and Allergy
Abstract

Resume La formation en allergologie en France en 2020 est dans une periode de transition ou se cotoient deux systemes d’enseignement, dont l’un est amene a disparaitre. L’ancien systeme associe le diplome d’etudes specialisees complementaires (DESC) allergologie et immunologie clinique pour les internes ayant passe le concours de l’internat avant 2017, et la capacite d’allergologie pour les medecins theses. Le nouveau systeme, depuis 2017, associe le diplome d’etudes specialisees (DES) allergologie et la formation specialisee transversale (FST) maladies allergiques pour les internes en formation et la capacite d’allergologie pour les medecins theses. En 2020, les 4 formations (DESC, DES, FST et capacite d’allergologie) coexistent.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results